Timing Is Everything…Or Is It?

The market's rally, especially in small-cap, continued this past week and Tailwinds' stocks participated along with the broader indexes. In particular, performance of our...

Moving Week

What do Donald Trump and I have in common? We are both in the process of moving... This week we found out that Joe Biden...

Provention Bio Completes Rolling Submission of the Biologics License Application (BLA) for Teplizumab for...

Tailwinds' Take: expected, but nice to see the company is on schedule with their submission. PRVB has a blockbuster drug here and will likely...

The Final Push…

Like the debate, 2020 has been a sh**-show. Pandemics, political divisiveness, fires...it's not been a beach party to say the least. Yet, here we stand...

Provention Bio Files Clinical Module for Teplizumab for the Delay or Prevention of Clinical...

Tailwinds' Take: an important step towards a BLA filing, which remains on track for sometime in Q4. We believe PRVB will trade higher into...

Shaking Things Up…

One of my investors recently told me that he diversifies his portfolio on his own. The money I manage for him is meant to...

OnTrak For A Great Year

Telehealth was the all the rage this past week. First The Centers for Medicare & Medicaid Services (CMS) is proposing changes to expand telehealth...

Provention Bio Reports Second Quarter 2020 Financial Results and Provides Business Update

Tailwinds' Take: we are getting very close to the FDA BLA submission in Q4, which will be the major catalyst to get shares in...

Random Thoughts on a Number of Stocks…

There's certainly a lot going on in the world at large right now and none of it seems too good. Covid-19 refuses to go...

Previewing the 2nd Half of 2020…and Other Updates From The Week

Greetings from...wait for it...Ashland Oregon. Yes, it was so good, we came back for more. The weather here is great, the riding is outstanding...

Provention Bio’s Teplizumab Continued to Significantly Delay the Onset of Insulin-Dependent Type 1 Diabetes...

Tailwinds' Take: excellent news for PRVB. Filing of IND in Q4 and approval early next year should be very big catalysts for this stock. OLDWICK,...

Provention Bio and Vactech Announce Publication of Proof-of-Concept Data for a Preclinical Prototype of...

OLDWICK, N.J. and TAMPERE, Finland, May 18, 2020 /PRNewswire/ --  Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing...

Bada Bing Bada Boom

As if on cue, the market took a turn lower last week. This will be but a quick note on the market, as I'm...

The Week In Review

The market continues to ignore my bearish calls and, instead, keeps chugging higher. I'm at a loss to explain this, as are most professional...

Provention Bio Reports First Quarter 2020 Financial Results and Provides Business Update

Tailwinds' Take: all systems go for tepluzimab. We expect the stock to continue performing well as the company gets closer to the anticipated approval...

Saturday Morning Ramblings…

Another great week in the market. The economy is in free-fall, unemployment is skyrocketing and stocks can't stop going up. How is this possible?...

Provention Bio Initiates Rolling Submission of Biologic License Application for Teplizumab for the Delay...

Tailwinds' Take: nice to see that everything remains on track for PRVB. We expect to see the filing completed by year-end with PDUFA date...

IF Alpha?

My biggest concern last fall was, "what if Bernie gets into office?" This fear was driven partially by the fact that the market would...

Chardan Research Investor Call Summary

Tailwinds' Take: although PRVB remains one of my larger holdings, I haven't written much about it lately. That's because we're really in a holding...

There’s Blood In The Streets…

Normally I love my Saturday mornings. This is when I write the weekly newsletter and it gives me a chance to review the prior...
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.